“Project Recode” aims to make human cells invulnerable to infection
A genome-writing consortium announced today that it intends to revise the genome of human cells in the lab so they resist viruses.
What’s recoding? A person’s genome uses three-letter “codons” (think AGT or CAT) to direct the assembly of proteins. But it turns out there are extra codons that aren’t needed. The plan is simple: get rid of them. That’s going to take some heavy-duty gene editing—more than 400,000 changes to about 20,000 human genes.
Who’s behind it: The project is the first big announcement by GP-Write, a private organization trying to hurry us up to the point where we can easily print human genomes. So far it lacks serious funding, but a gene-editing company, Cellectis, says it will donate its technology to the cause. The effort is expected to take about a decade.
Bad for viruses: Viruses use the missing codons to propagate in cells, so a recoded cell would be essentially virus-proof. The researchers say such “ultra-safe” cells could be good for the biotech industry, which uses human cells to manufacture drugs.
Are virus-proof people coming? That’s certainly a possibility, according to project leader George Church of Harvard Medical School. He once wrote that recoded humans would be the “climax” of synthetic biology.
Deep Dive
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
After 25 years of hype, embryonic stem cells are still waiting for their moment
Research roadblocks and political debates have delayed progress—but scientists are inching closer to delivering a cure.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.